SBM.V - Sirona Biochem Corp.

TSXV - TSXV Delayed Price. Currency in CAD

Sirona Biochem Corp.

889 West Pender Street
Suite 605
Vancouver, BC V6C 3B2
Canada

http://www.sironabiochem.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Howard J. Verrico M.D.Founder, Chairman, CEO & Sec.144kN/A1961
Mr. Christopher D. HoptonCFO & Director132kN/A1966
Dr. Géraldine Deliencourt-GodefroyChief Scientific Officer & Director213.39kN/AN/A
Ms. Michelle Seltenrich MBAVP of OperationsN/AN/AN/A
Dr. Brett A. Premack Ph.D.Scientific ConsultantN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Sirona Biochem Corp. operates as a cosmetic ingredient and drug discovery company in Canada and France. The company develops programs in three areas, including diabetes, anti-inflammatories, and anti-infectives for therapeutics; anti-aging and depigmenting agents in cosmeceuticals; and biological ingredients, such as inducers and adjuvants for the biological development and preservation. It develops a sodium glucose co-transporter inhibitor for the treatment of diabetes, as well as cosmetic skin lightening agents and compounds. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. Sirona Biochem Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada.

Corporate Governance

Sirona Biochem Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.